avr262019

Patient Survey: Biosimilars for Treatment of Lymphoma and CLL

If you have been diagnosed with lymphoma or CLL, you can help by completing our survey.

Lymphoma Canada is preparing a submission for the pan-Canadian Oncology Drug Review (pCODR) for:

Truxima (a rituximab biosimilar drug) treatment of lymphoma and CLL.

The survey provides us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

The survey will be open until midnight Pacific Time on Friday, June 7th, and should only take 10 minutes of your time.

You may access the survey by clicking the link below.

Patient Survey - Biosimilars

Like with Social Media